CD163 and gastric cancer: This retrospective study aims to evaluate the prognostic impact of PD-L1 expression and CD4+/CD8+ TILs as well as CD163+ TAMs, and to develop a prognostic model incorporating the expression of PD-L1 and related TIICs for survival prediction in GC patients.